To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

• Status: Completed
• Trial end date: 2017-11-07
• Target enrollment: 0
• Participant gender: All

Summary

Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Participants must be first-generation Japanese (born in Japan and not living outside of Japan for > 10 years; both parents must be ethnically Japanese)

• Body Mass Index 18.0 to 25.0 kg/m2, inclusive

• Women must not be of nonchildbearing potential (cannot become pregnant)

Exclusion Criteria:

• Any significant acute or chronic medical illness

• History of allergy to BMS-986177 or other factor Xia inhibitors and/or formulation excipients or history of any significant drug allergy (such as anaphylaxis or hepatotoxicity)

• History or evidence of abnormal bleeding or coagulation disorder

Other protocol defined inclusion and exclusion criteria apply